Anbio Biotechnology (NNNN)
NasdaqGM: NNNN
· Real-Time Price · USD
9.89
-0.46 (-4.44%)
At close: Aug 12, 2026, 3:43 PM
9.86
-0.30%
After-hours: 4:30 PM
Anbio Biotechnology (NNNN) Stock Price, Analysis & Data
-4.44% (1D)
| Bid | 11.55 |
| Market Cap | 434.08M |
| Revenue (ttm) | 8.65M |
| Net Income (ttm) | 6.4M |
| Beta | n/a |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 65.93 |
| Forward PE | n/a |
| P/B (ttm) | 14.40 |
| P/S (ttm) | 50.20 |
| Earnings Date | n/a |
| Ask | 9.89 |
| Volume | 22,919 |
| Avg. Volume (20D) | 41,345 |
| Open | 10.38 |
| Previous Close | 10.35 |
| Day's Range | 9.56 - 10.47 |
| 52-Week Range | 8.30 - 54.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NNNN
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over...
Industry Medical Instruments & Supplies
Sector Healthcare
IPO Date Feb 19, 2025
Employees 27
Stock Exchange NasdaqGM
Ticker Symbol NNNN
Financial Performance
In 2025, Anbio Biotechnology's revenue was 8.65M, an increase of 5.64% compared to the previous year's 8.19M. Earnings were 6.4M, an increase of 169.86%.
Financial Statements
Page 1 of 2